DENVER — Primary generalized tonic-clonic seizures present unique challenges to adolescents diagnosed with the condition, Sunita Misra, MD, PhD, said in this Healio video at the American Academy of Neurology annual meeting.
“We are looking to see if cenobamate is effective for primary generalized tonic-clonic seizures,” said Misra, vice president of global clinical development and acting chief medical officer for SK Life Science.
The company has commenced a clinical trial in adolescents aged 12 to 17 years with primary generalized tonic-clonic seizures and it is hoping to